Results 221 to 230 of about 119,990 (313)

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

open access: yesiNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong   +5 more
wiley   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

open access: yesiNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little   +12 more
wiley   +1 more source

A New Paradigm: 46 Structural Cell Types Function as Environment‐Supporting Innate Immune Cells, With Endothelial and Vascular Smooth Muscle Cells as Key Prototypes

open access: yesiNew Medicine, EarlyView.
ABSTRACT The scope, organization, and biological significance of innate immune functions across structural cell types remain poorly defined. To address these fundamental knowledge gaps, we analyzed experimental data of transcriptomes generated by our group and others.
Juanjuan Liu   +22 more
wiley   +1 more source

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

open access: yesiNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai   +4 more
wiley   +1 more source

TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis

open access: yesiNew Medicine, EarlyView.
ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley   +1 more source

Home - About - Disclaimer - Privacy